TARGET GROUP INC.
Target Group Inc. (CBDY)
Overview
Target Group Inc. is a small, OTC-traded, vertically integrated cannabis company operating primarily through its wholly-owned Canadian subsidiary, Canary Rx Inc. Canary holds a Health Canada cannabis cultivation license and operates a 44,000-square-foot licensed cultivation and processing facility in Norfolk County, Ontario. The company has struggled financially: for the quarter ended March 31, 2025, revenue was $1.4 million, down from $1.9 million in the year-earlier quarter, and the company reported a working capital deficit of $9.9 million and an accumulated deficit of $31 million as of that date, with its auditors flagging substantial doubt about its ability to continue as a going concern. Target's most recent 10-K, filed March 2026 for fiscal year 2025, states management's expectation that operations will generate positive cash flow "starting in 2026," a target the company has yet to demonstrate.
What They Do & How They Make Money
Target Group generates revenue by cultivating, processing, and selling cannabis and cannabis-derived products through Canary, which sells to a concentrated base of roughly a dozen wholesale/provincial customers as well as, following a recent licensing update, directly to Canadian provincial retail boards for consumer products. A notable feature of the business is Canary's partnership with Serious Seeds B.V., a well-regarded Dutch cannabis breeder, under which Canary cultivates what the companies describe as "exclusive, world-class proprietary genetics" — an attempt to differentiate its flower and derivative products in an otherwise highly commoditized Canadian cannabis market. In April 2023, Target consolidated its previously 50%-owned joint venture (JVCo) into full ownership, simplifying its corporate structure but also concentrating cannabis-cultivation risk entirely on its own balance sheet.
Competitors
Target/Canary competes in Canada's crowded, oversupplied licensed cannabis cultivation market against:
- Large Canadian licensed producers such as Canopy Growth, Tilray, and Aurora Cannabis, which have far greater scale, brand recognition, and provincial-board distribution relationships.
- Numerous smaller and mid-size Canadian craft and licensed cultivators competing on price and genetics in an industry that has seen chronic oversupply and falling wholesale flower prices since Canadian legalization.
- Illicit/grey-market cannabis sources, which continue to undercut licensed producers on price in parts of the Canadian market.
Competitive Position
Target's principal claimed differentiator — exclusive proprietary genetics through the Serious Seeds partnership — is a genuine, if modest, form of product differentiation in an industry where most flower is otherwise treated as a commodity. Its new authorization to sell directly to provincial retail boards for consumer products is also incrementally positive, potentially improving margins versus pure wholesale distribution. However, the company's financial position undercuts any competitive advantage: declining year-over-year revenue, a $9.9 million working capital deficit, a $31 million accumulated deficit, and explicit going-concern doubt all signal a business struggling simply to fund operations, let alone invest in scale or brand-building against much larger Canadian licensed producers. The Canadian cannabis cultivation industry overall remains oversupplied and price-competitive, offering little structural protection to any single small player. Target's outlook depends on whether its genetics partnership and new retail-board access can turn around revenue and margins before its balance sheet strain forces further dilution or restructuring.